Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek(R) 2025
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek(R) 2025 Results from Hengrui's completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss, to be presented in an oral session GlobeNewswire October 21, 2025 SHANGHAI and WALTHAM, Mass., Oct. 21, 2025 (GLOBE […]